Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Study: Actos Bladder Cancer Risk Confirmed

Filed December 4th, 2012 admin

Results of a new study add increasing evidence to the notion that steady use of the Type 2 diabetes drug, Actos, increases the chance of developing bladder cancer.

The information comes from interim results of a study among Kaiser Permanente Northern California patients recorded between January 1997 and December 2010; Kaiser and Takeda Global Research and Development Center Inc. conducted the research. Data will be collected through 2013.

The study compared bladder cancer risks among Actos users and non-Actos users. There were more than 33,000 patients in the Actos group who filed at least two Actos prescriptions within a six-month timeframe. The other group featured close to 16,000 patients who were treated with other drugs for their Type 2 diabetes. The evidence showed that bladder cancer diagnosis for those who took Actos was 82.3 per 100, 000 person years, compared to 72.6 per 100,000 years for those not taking Actos. The number for those who have been treated with Actos for more than three years jumped to 87.8 per 100,000.

The results indicate a direct correlation between the use of Actos and the development of bladder cancer. Actos has been surrounded by controversy on a global level. In June 2011, the drug had its sales suspended by medical regulators in Germany and France after a possible bladder cancer risk was detected. Meanwhile, a May 2011 study looking at adverse event reports to the U.S. Food and Drug Administration (FDA) between 2004-2009, found that patients faced a disproportionate risk of developing bladder cancer when taking Actos for more than two years.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!